VELCADE

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug VELCADE contains one active pharmaceutical ingredient (API):

1 Bortezomib UNII 69G8BD63PP - BORTEZOMIB

Bortezomib is a proteasome inhibitor. It is specifically designed to inhibit the chymotrypsin-like activity of the 26S proteasome in mammalian cells. Inhibition of the 26S proteasome prevents this targeted proteolysis and affects multiple signalling cascades within the cell, ultimately resulting in cancer cell death. Read about Bortezomib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
VELCADE Powder for solution	European Medicines Agency (EU)	MPI, EU: SmPC
Velcade 3.5 mg powder for solution for injection	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01XG01	Bortezomib	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XG Proteasome inhibitors
Discover more medicines within L01XG01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 12219D, 12227M
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 514506401156317
Country: CA	Health Products and Food Branch	Identifier(s): 02262452
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 27.605-1-03-12
Country: EE	Ravimiamet	Identifier(s): 1148004, 1364868
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 04274001
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 017195
Country: FR	Base de données publique des médicaments	Identifier(s): 62438913, 69756861
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 75131
Country: HK	Department of Health Drug Office	Identifier(s): 60429, 63741
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 4829
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291412D1024
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1031151, 1032114
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 654M2004
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 75299, 93610
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 11690, 13403
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100085192, 100194113
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W42249001, W53033001
Country: SG	Health Sciences Authority	Identifier(s): 13064P
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 15273011H
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699593775017
Country: US	FDA, National Drug Code	Identifier(s): 63020-049
Country: ZA	Health Products Regulatory Authority	Identifier(s): 43/26/0427, A40/26/0005